Home
  >  
Section 81
  >  
Chapter 80,278

RAGE: a potential target for Abeta-mediated cellular perturbation in Alzheimer's disease

Chen, X.; Walker, D.G.; Schmidt, A.M.; Arancio, O.; Lue, L.-F.; Yan, S.D.

Current Molecular Medicine 7(8): 735-742

2007

ISSN/ISBN: 1566-5240
PMID: 18331231
Accession: 080277165
Download citation:  
Text
  |  
BibTeX
  |  
RIS
This review focuses on the current findings regarding interaction between amyloid beta peptide (Abeta) and receptor for advanced glycation endproducts (RAGE) and its roles in the pathogenesis of Alzheimer's disease (AD). As a ubiquitously expressed cell surface receptor, RAGE mediates the effects of Abeta on microglia, blood-brain barrier (BBB) and neurons through activating different signaling pathways. Data from autopsy brain tissues, in vitro cell cultures and transgenic mouse models suggest that Abeta-RAGE interaction exaggerates neuronal stress, accumulation of Abeta, impaired learning memory, and neuroinflammation. Blockade of RAGE protects against Abeta-mediated cellular perturbation. These findings may have an important therapeutic implication for neurodegenerative disorders relevant to AD.

PDF emailed within 1 workday: $29.90




Related References

Yan, S.S.; Chen, D.; Yan, S.; Guo, L.; Du, H.; Chen, J.X. 2012: RAGE is a key cellular target for Abeta-induced perturbation in Alzheimer's disease Frontiers in Bioscience 4(1): 240-250
Yan, S.D.; Bierhaus, A.; Nawroth, P.P.; Stern, D.M. 2009: RAGE and Alzheimer's disease: a progression factor for amyloid-beta-induced cellular perturbation? Journal of Alzheimer's Disease: Jad 16(4): 833-843
Maier, M.; Seabrook, T.J.; Lazo, N.D.; Jiang, L.; Das, P.; Janus, C.; Lemere, C.A. 2006: Short amyloid-beta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimer's disease mouse model in the absence of an Abeta-specific cellular immune response Journal of Neuroscience: the Official Journal of the Society for Neuroscience 26(18): 4717-4728
Marques, A.T.; Fernandes, P.A.; Ramos, M.J. 2009: ABAD: a potential therapeutic target for Abeta-induced mitochondrial dysfunction in Alzheimer's disease Mini Reviews in Medicinal Chemistry 9(8): 1002-1008
Yan, S.D.; Stern, D.; Kane, M.D.; Kuo, Y.M.; Lampert, H.C.; Roher, A.E. 1998: RAGE-Abeta interactions in the pathophysiology of Alzheimer's disease Restorative Neurology and Neuroscience 12(2-3): 167-173
Mitchell, M.B.; Buccafusco, J.J.; Schade, R.F.; Webster, S.J.; Mruthinti, S.; Harrell, D.U.; Gulati, N.K.; Miller, L.S. 2010: RAGE and Abeta immunoglobulins: relation to Alzheimer's disease-related cognitive function Journal of the International Neuropsychological Society: Jins 16(4): 672-678
Holtzman, D.M.; Bales, K.R.; Paul, S.M.; DeMattos, R.B. 2002: Abeta immunization and anti-Abeta antibodies: potential therapies for the prevention and treatment of Alzheimer's disease Advanced Drug Delivery Reviews 54(12): 1603-1613
Mruthinti, S.; Buccafusco, J.J.; Hill, W.D.; Waller, J.L.; Jackson, T.W.; Zamrini, E.Y.; Schade, R.F. 2004: Autoimmunity in Alzheimer's disease: increased levels of circulating IgGs binding Abeta and RAGE peptides Neurobiology of Aging 25(8): 1023-1032
Cho, H.J.; Son, S.M.; Jin, S.M.; Hong, H.S.; Shin, D.H.; Kim, S.J.; Huh, K.; Mook-Jung, I. 2009: RAGE regulates BACE1 and Abeta generation via NFAT1 activation in Alzheimer's disease animal model Faseb Journal: Official Publication of the Federation of American Societies for Experimental Biology 23(8): 2639-2649
Nath, A.; Hall, E.; Tuzova, M.; Dobbs, M.; Jons, M.; Anderson, C.; Woodward, J.; Guo, Z.; Fu, W.; Kryscio, R.; Wekstein, D.; Smith, C.; Markesbery, W.R.; Mattson, M.P. 2003: Autoantibodies to amyloid beta-peptide (Abeta) are increased in Alzheimer's disease patients and Abeta antibodies can enhance Abeta neurotoxicity: implications for disease pathogenesis and vaccine development Neuromolecular Medicine 3(1): 29-39
Fang, F.; Lue, L-Fen.; Yan, S.; Xu, H.; Luddy, J.S.; Chen, D.; Walker, D.G.; Stern, D.M.; Yan, S.; Schmidt, A.Marie.; Chen, J.X.; Yan, S.ShiDu. 2010: RAGE-dependent signaling in microglia contributes to neuroinflammation, Abeta accumulation, and impaired learning/memory in a mouse model of Alzheimer's disease Faseb Journal: Official Publication of the Federation of American Societies for Experimental Biology 24(4): 1043-1055
Cotman, S.L.; Halfter, W.; Cole, G.J. 2000: Agrin binds to beta-amyloid (Abeta), accelerates abeta fibril formation, and is localized to Abeta deposits in Alzheimer's disease brain Molecular and Cellular Neurosciences 15(2): 183-198
M.W.ksler; P.S.abo; B.A.amiak; T.B.rgut; C.M.nthe; S.Y.unkin; L.Y.unkin; N.R.lkin 2008: Infusion of intravenous immunoglobulin (IVIg) containing anti-abeta antibodies is associated with a decrease of Abeta in cerebrospinal fluid (CSF) and increase of Abeta in blood from 8 patients with mild Alzheimer's disease (AD) Journal of Allergy and Clinical Immunology 121(2-supp-S1)
Arancio, O.; Zhang, H.Ping.; Chen, X.; Lin, C.; Trinchese, F.; Puzzo, D.; Liu, S.; Hegde, A.; Yan, S.Fang.; Stern, A.; Luddy, J.S.; Lue, L-Fen.; Walker, D.G.; Roher, A.; Buttini, M.; Mucke, L.; Li, W.; Schmidt, A.Marie.; Kindy, M.; Hyslop, P.A.; Stern, D.M.; Du Yan, S.Shi. 2004: RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice EMBO Journal 23(20): 4096-4105
Yao, J.; Du, H.; Yan, S.; Fang, F.; Wang, C.; Lue, L.-F.; Guo, L.; Chen, D.; Stern, D.M.; Gunn Moore, F.J.; Xi Chen, J.; Arancio, O.; Yan, S.S. 2011: Inhibition of amyloid-beta (Abeta) peptide-binding alcohol dehydrogenase-Abeta interaction reduces Abeta accumulation and improves mitochondrial function in a mouse model of Alzheimer's disease Journal of Neuroscience: the Official Journal of the Society for Neuroscience 31(6): 2313-2320
Deane, R.J. 2012: Is RAGE still a therapeutic target for Alzheimer's disease? Future Medicinal Chemistry 4(7): 915-925
Warrier, S.; Marimuthu, R.; Sekhar, S.; Bhuvanalakshmi, G.; Arfuso, F.; Das, A.K.; Bhonde, R.; Martins, R.; Dharmarajan, A. 2016: SFRP-mediated Wnt sequestration as a potential therapeutic target for Alzheimer's disease International Journal of Biochemistry and Cell Biology 75: 104-111
Wang, X.; Yu, S.; Gao, S.-J.; Hu, J.-P.; Wang, Y.; Liu, H.-X. 2014: Insulin inhibits Abeta production through modulation of APP processing in a cellular model of Alzheimer's disease Neuro Endocrinology Letters 35(3): 224-229
Maczurek, A.; Shanmugam, K.; Münch, G. 2008: Inflammation and the redox-sensitive AGE-RAGE pathway as a therapeutic target in Alzheimer's disease Annals of the new York Academy of Sciences 1126: 147-151
Arispe, N.; Diaz, J.C.; Simakova, O. 2007: Abeta ion channels. Prospects for treating Alzheimer's disease with Abeta channel blockers Biochimica et Biophysica Acta 1768(8): 1952-1965